972 filings
Page 6 of 49
8-K
lyov j3xqa8rj
28 Jul 22
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
9:00am
8-K
vdf03n
18 Jul 22
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
8:45am
8-K
117oeawgea
29 Jun 22
Regulation FD Disclosure
9:03am
8-K
ub4cw6w0rmkonruv804
27 Jun 22
Other Events
9:00am
4
prj9q3enhu3ost6
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:06pm
3
zpakj87qj6l3plghro
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:04pm
8-K
yirecsc
21 Jun 22
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
8:37am
8-K
gk75ja1
7 Jun 22
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
9:00am
8-K
detyhdbn wr7n
31 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
lhz4x rf8m
23 May 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
8vpqanii l9d2vf1
17 May 22
Other Events
4:21pm
424B2
zegufh80j4ouq 4sj9
17 May 22
Prospectus for primary offering
4:12pm
8-K
te09hf c2f1t
16 May 22
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
12:00am
8-K
uhfnpc7lgw
9 May 22
Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
9:01am
8-K
u3z70vq41zgvt442
6 May 22
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
9:00am
424B3
5ai5433bqqwhl
3 May 22
Prospectus supplement
4:01pm
EFFECT
od90c6qyzxn3t9
3 May 22
Notice of effectiveness
12:15am
CORRESP
z0n7qk7qxt1f
28 Apr 22
Correspondence with SEC
12:00am